Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailHepatic insulin resistance in obese non-diabetic subjects and in type 2 diabetic patients.
Paquot, Nicolas ULg; Scheen, André ULg; Dirlewanger, Mirjam et al

in Obesity Research (2002), 10(3), 129-34

OBJECTIVE: Obese non-diabetic patients are characterized by an extra-hepatic insulin resistance. Whether obese patients also have decreased hepatic insulin sensitivity remains controversial. RESEARCH ... [more ▼]

OBJECTIVE: Obese non-diabetic patients are characterized by an extra-hepatic insulin resistance. Whether obese patients also have decreased hepatic insulin sensitivity remains controversial. RESEARCH METHODS AND PROCEDURES: To estimate their hepatic insulin sensitivity, we measured the rate of exogenous insulin infusion required to maintain mildly elevated glycemia in obese patients with type 2 diabetes, obese non-diabetic patients, and lean control subjects during constant infusions of somatostatin and physiological low-glucagon replacement infusions. To account for differences in insulin concentrations among the three groups of subjects, an additional protocol was also performed in healthy lean subjects with higher insulin infusion rates and exogenous dextrose infusion. RESULTS: The insulin infusion rate required to maintain glycemia at 8.5 mM was increased 4-fold in obese patients with type 2 diabetes and 1.5-fold in obese non-diabetic patients. The net endogenous glucose production (measured with 6,6-(2)H(2)-glucose) and total glucose output (measured with 2-(2)H(1)-glucose) were approximately 30% lower in the patients than in the lean subjects. Net endogenous glucose production and total glucose output were both markedly increased in both groups of obese patients compared with lean control subjects during hyperinsulinemia. DISCUSSION: Our data indicate that both obese non-diabetic and obese type 2 diabetic patients have a blunted suppressive action of insulin on glucose production, indicating hepatic and renal insulin resistance. [less ▲]

Detailed reference viewed: 25 (1 ULg)
Full Text
Peer Reviewed
See detailHépatite à virus G: mythe ou réalité? VHG/GBV-C: diagnostic, épidémiologie, risque transfusionnel et pathogénicité
Gerard, Christiane ULg; Vaira, Dolorès ULg; Delwaide, Jean ULg et al

in Revue Médicale de Liège (1998), 53(9), 524-528

The recently discovered G virus (also called either GBV-C or HGV) is transmitted by blood transfusion as well as by sexual intercourse. The global prevalence of GBV-C is high, not only in those groups ... [more ▼]

The recently discovered G virus (also called either GBV-C or HGV) is transmitted by blood transfusion as well as by sexual intercourse. The global prevalence of GBV-C is high, not only in those groups classically known to be exposed to parenteral risks (i.v. drug users, polytransfused patients), but also in the blood donors population. The diagnosis of active infection lies on the search of GBV-C RNA by Polymerase Chain Reaction whereas that of resolved (past) infection lies on the presence of specific antibodies. Till now, it has not been possible to correlate convincingly the presence of GBV-C RNA with any acute or chronic hepatopathy. On the contrary, a lot of arguments tend to suggest that the GBV-C is not pathogenic for the liver, although some modes of transmission are common with those of other (known and probably not known) hepatotropic viruses. According to the actual knowledge of the consequences of GBV-C infection, it appears as non relevant to instaure a systematic screening of this new virus in blood donors. [less ▲]

Detailed reference viewed: 32 (2 ULg)
Full Text
See detailHépatite C: dépistage, traitement et prévention. Recommandations pratiques-résumé
Brenard, R.; Michielsen, P.; Bourgeois, N. et al

in La Revue de la Medicine Generale (2003), 205

Detailed reference viewed: 11 (0 ULg)
Full Text
Peer Reviewed
See detailL'hépatite E : une hépatite du tiers-monde présente en Belgique
Seivert, Maxime ULg; Belaiche, Jacques ULg; Delwaide, Jean ULg

in Revue Médicale de Liège (2008), 63

Detailed reference viewed: 121 (14 ULg)
See detailL'hépatite E
Delwaide, Jean ULg; Gerard, Christiane ULg

in Les Hépatites virales, Roche (1998)

Detailed reference viewed: 13 (0 ULg)
See detailHépatites C et B: attitude en cas de risque de contamination, traitement des formes aiguës et chroniques
Delwaide, Jean ULg

in Traité de Médecine Hospitalière (2006)

Detailed reference viewed: 13 (3 ULg)
Full Text
See detailHépatites C sporadiques. Risque iatrogène non négligeable
Delwaide, Jean ULg

in Interface (2000), 6

On estime à plus de 150 millions le nombre d'individus infectés par le virus de l'hépatite C dans le monde. En Belgique, cette prévalence est estimée à 10/0, et la plupart des nouvelles contaminations se ... [more ▼]

On estime à plus de 150 millions le nombre d'individus infectés par le virus de l'hépatite C dans le monde. En Belgique, cette prévalence est estimée à 10/0, et la plupart des nouvelles contaminations se retrouvent chez les toxicomanes utilisant des drogues intraveineuses. Les transmissions en milieu hospitalier pourraient cependant rendre compte d'une part non négligeable des hépatites C dites «sporadiques», dont le mode de transmission n'est jusqu'ici pas élucidé. [less ▲]

Detailed reference viewed: 42 (2 ULg)
Full Text
Peer Reviewed
See detailHepatitis B virus and hepatitis C virus infection in Belgium: similarities and differences in epidemic and initial management
De Vroey, B; Moreno, C; Laleman, W et al

in European Journal of Gastroenterology & Hepatology (2013), 25(5), 613-619

Introduction Nationwide studies comparing patients with hepatitis B and C virus (HBV and HCV) infections are mandatory for assessing changes in epidemiology. Aim The aim of this study was to compare ... [more ▼]

Introduction Nationwide studies comparing patients with hepatitis B and C virus (HBV and HCV) infections are mandatory for assessing changes in epidemiology. Aim The aim of this study was to compare epidemiological data and initial management of newly diagnosed patients with persistent HBV (HBsAg positive) or HCV (detectable HCV RNA) infection in Belgium. Patients and methods Data were extracted from two Belgian observational databases. Results A total of 655 patients (387 HBV and 268 HCV) were included. Compared with HCV patients, HBV patients were younger, more frequently men, more often of Asian or African origin (43 vs. 10%, P < 0.0001), and less frequently contaminated by transfusion or intravenous drug use (9 and 6% vs. 34 and 44%, P< 0.0001). Viral replication was assessed in 89% of HBV patients. Compared with HCV patients, HBV patients more frequently had normal alanine aminotransferase (ALT) levels (65 vs. 29%, P < 0.0001), less frequently underwent liver biopsy (29 vs. 67%, P < 0.0001), and were less often considered for antiviral therapy (25 vs. 54%, P < 0.0001). When taking only HBV patients with detectable viral replication into consideration, results remained unchanged. During the multivariate analysis, ALT was a major factor for performing liver biopsy or considering antiviral therapy in both groups. Conclusion HBV and HCV screening policies should be targeted toward immigrants and intravenous drug users, respectively. Guidelines recommending systematic search for viral replication should be reinforced in HBV patients. HBV patients less frequently underwent liver biopsy and were less often considered for antiviral therapy compared with HCV patients. Despite the lack of sensitivity and specificity, ALT remains a pivotal decision-making tool for liver biopsy and antiviral therapy in both infections. [less ▲]

Detailed reference viewed: 21 (0 ULg)
Full Text
Peer Reviewed
See detailHepatitis C genotype 4 response rate to pegylated interferon and ribavirin treatment in Belgium is similar to genotype 1
de Galocsy, C.; Kaufman, L.; Tomasovic, S. et al

in Acta Gastro-Enterologica Belgica (2010), 73

Background and aims : Patients with genotype 4 (G4) chronic hepatitis C from the Middle East respond better to treatment than genotype 1 (G1) patients. There are few data on the response rates to ... [more ▼]

Background and aims : Patients with genotype 4 (G4) chronic hepatitis C from the Middle East respond better to treatment than genotype 1 (G1) patients. There are few data on the response rates to treatment of G4 patients living in Western Europe. Many G4 patients in Belgium originate from Central Africa, and their response to treatment seems lower. Methods : We analysed the data from 2 randomized phase III studies conducted in Belgium, BerNar-1 and BerNar-2, comparing the sustained virological response (SVR) to pegylated interferon and ribavirin of 78 G4 patients (34 Caucasians, 44 Blacks) and 477 G1 patients (455 Caucasians, 12 Blacks), and assessing the predictors of SVR. Results : Baseline characteristics of G4 and G1 patients were similar except mainly for race. Complete early virological response (cEVR) was similar in G4 (73.2%) and G1 (68.1%). cEVR was also similar between Black and Caucasian G4 and between Black and Caucasian G1 patients. Partial early virological response was similar for G4 and G1. SVR was similar for G4 (51.3%) and G1 (51.8%). There was a trend for a higher SVR in Caucasians than in Blacks. In multivariate analysis, the only predictors for SVR were the presence of cirrhosis, HCV viral load, age < 40 vs 40 yrs, and treatment status (relapsers vs naïve). Conclusions : G4 patients in Belgium have the same SVR as G1 patients. It is lower than the SVR described in Arab countries, especially for Black G4 patients. (Acta gastro enterol. belg., 2010, 73, 229-234). [less ▲]

Detailed reference viewed: 28 (3 ULg)
Full Text
Peer Reviewed
See detailHepatitis C infection: eligibility for antiviral therapies
Delwaide, Jean ULg; El Saouda, R.; Gerard, Christiane ULg et al

in European Journal of Gastroenterology & Hepatology (2005), 17(11), 1185-1189

Background Current treatments of chronic hepatitis C virus (HCV) are effective, but expensive and susceptible to induce significant side effects. Objectives To evaluate the proportion of HCV patients who ... [more ▼]

Background Current treatments of chronic hepatitis C virus (HCV) are effective, but expensive and susceptible to induce significant side effects. Objectives To evaluate the proportion of HCV patients who are eligible for a treatment. Methods In a database comprising 1726 viraemic HCV patients, the files of 299 patients who presented to the same hepatologist for an initial appointment between 1996 and 2003 were reviewed. Results Patients' characteristics were age 43.1 +/- 15.6 years, 53% male and 92% Caucasian. The main risk factors were transfusion (43%) and drug use (22%). Genotypes were mostly genotype 1 (66%), genotype 3 (12%) and genotype 2 (10%). These characteristics were not different from those of the whole series of 1726 patients. A total of 176 patients (59%) were not treated, the reasons for non-treatment being medical contraindications (34%), non-compliance (25%) and normal transaminases (24%). In addition, 17% of patients declined therapy despite being considered as eligible, mainly due to fear of adverse events. Medical contraindications were psychiatric (27%), age (22%), end-stage liver disease (15%), willingness for pregnancy (13%), cardiac contraindication (7%) and others (16%). Only 123 patients (41%) were treated. A sustained viral response was observed in 41%. The treatment was interrupted in 16% for adverse events. Conclusions The majority of HCV patients are not eligible for treatment. This implies that, with current therapies, only 17% of patients referred for chronic HCV become sustained responders. Some modifications of guidelines could extend the rate of treatment (patients with normal transaminases), but an important barrier remains the patients' and the doctors' fear of adverse events. [less ▲]

Detailed reference viewed: 24 (5 ULg)
Full Text
Peer Reviewed
See detailHepatitis C of genotype 2: the role of medical invasive exams.
Putzeys, V.; GERARD, Christiane ULg; Bastens, B. et al

in Acta gastro-enterologica Belgica (2011), 74(2), 277-80

BACKGROUND AND AIM: Hepatitis C virus genotype 2 is the third in order of frequency in Belgium. The aim of this study was to better define the genotype 2 carriers' epidemiology characteristics. METHODS ... [more ▼]

BACKGROUND AND AIM: Hepatitis C virus genotype 2 is the third in order of frequency in Belgium. The aim of this study was to better define the genotype 2 carriers' epidemiology characteristics. METHODS: In a database comprising 1726 viremic hepatitis C virus patient from the south part of Belgium, the files of 98 genotype 2 carriers were reviewed. RESULTS: There was a strong association between genotype 2 and the mode of transmission. The rate of contamination by invasive medical exams was very high (23%), and statistically different from the one of the others genotypes. Eligibility for antiviral therapies and the rate of sustained viral response were high. CONCLUSION: HCV genotype 2 was highly associated with transmission by invasive medical exams. [less ▲]

Detailed reference viewed: 83 (13 ULg)
Full Text
Peer Reviewed
See detailHepatitis C virus genotype 5 in southern Belgium: Epidemiological characteristics and response to therapy
Delwaide, Jean ULg; Gerard, Christiane ULg; Reenaers, Catherine ULg et al

in Digestive Diseases & Sciences (2005), 50(12), 2348-2351

Data are scarce on patients infected with hepatitis C virus of genotype 5, due to the low prevalence of this genotype around the world. To better define the characteristics of these patients, we reviewed ... [more ▼]

Data are scarce on patients infected with hepatitis C virus of genotype 5, due to the low prevalence of this genotype around the world. To better define the characteristics of these patients, we reviewed the files of 16 genotype 5 patients. Mean age was 38 +/- 14. All patients were of European origin. Most of them (75%) had been contaminated by transfusion within a short time period (between 1980 and 1991). There were no intravenous drug addicts. Seven patients received treatment. One patient did not respond to interferon (IFN) monotherapy. Of four patients treated with IFN and ribavirin, three became sustained viral responders. Two patients treated with pegylated IFN and ribavirin became sustained viral responders. In our region, genotype 5 patients seem to have been contaminated within a relatively short time period. Treatment with IFN or pegylated IFN and ribavirin gave a high rate (83%) of sustained viral responses. [less ▲]

Detailed reference viewed: 43 (8 ULg)
Full Text
Peer Reviewed
See detailHepatitis C virus transmission following invasive medical procedures
Delwaide, Jean ULg; Gerard, Christiane ULg; Vaira, Dolorès ULg et al

in Journal of Internal Medicine (1999), 245(1), 107-108

Detailed reference viewed: 55 (6 ULg)
Full Text
Peer Reviewed
See detailHepatitis C: screening, treatment and prevention practical guidelines
Michielsen, P.; Brenard, R.; Bourgeois, N. et al

in Acta Gastro-Enterologica Belgica (2003), 66(1), 15-19

The standard treatment for patients with chronic hepatitis C is a 6-12-month combination therapy with interferon alpha and ribavirin. Induction treatment could result in a faster early decline of the ... [more ▼]

The standard treatment for patients with chronic hepatitis C is a 6-12-month combination therapy with interferon alpha and ribavirin. Induction treatment could result in a faster early decline of the hepatitis C virus (HCV) load and a better response rate. Naive chronically infected HCV patients (n = 454) were randomized into two arms to receive either induction treatment with interferon alpha 2b 5 million units (MU) subcutaneously (s.c.) daily during a period of 8 weeks (arm A); or treatment with interferon alpha 2b 5 MU s.c. three times a week (TIW) for a period of 8 weeks (arm B). After week 8, interferon treatment in both arms was 3 MU s.c. TIW for a total period of 12 months. In both arms, ribavirin (1000-1200 mg orally per day) was added at week 4. Induction treatment resulted in a higher virological response at week 8 of treatment (66%vs 47%; P < 0.01). However, response at the end of treatment and at 6 months follow-up was not different (53%vs 50%, 41%vs 33%). The occurrence of adverse events and the drop-out rate were similar in both arms. Although an early virological response is observed more frequently in the induction treatment, end of treatment response and sustained responses did not differ [less ▲]

Detailed reference viewed: 19 (0 ULg)
See detailHepatitis E virus infection in domestic swine in Belgium
Thiry, Damien ULg; Mauroy, Axel ULg; Brochier, Bernard et al

Poster (2012, August)

Detailed reference viewed: 5 (1 ULg)
See detailHepatitis E virus infection in domestic swine, wild boar and human in Belgium
Thiry, Damien ULg; Mauroy, Axel ULg; Brochier, Bernard et al

Conference (2012, September)

Detailed reference viewed: 6 (1 ULg)
See detailHepatitis E virus infection in domestic swine, wild boar and human in Belgium
Thiry, Damien ULg; Mauroy, Axel ULg; Brochier, Bernard et al

Conference (2012, October)

Detailed reference viewed: 8 (0 ULg)
See detailHepatitis E virus infection in suids and cervids in southern Belgium
Thiry, Damien ULg; Mauroy, Axel ULg; Fett, Thomas ULg et al

Conference (2014, April)

Detailed reference viewed: 9 (3 ULg)